

**One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Long-term Clinical Outcomes of Peripheral Endovascular Device Interventions** Jihad Mustapha et al.

**Supplementary Appendix 1. LIBERTY 360° Sites, Principal Investigators, and Steering Committee.**

1. Metro Health Hospital, Wyoming, MI (Jihad Mustapha, Larry Diaz)
2. Coastal Vascular and Interventional, Pensacola, FL (Huey McDaniel)
3. Mid-Michigan Heart and Vascular Center, P.C., Mt. Pleasant, MI (John McClure)
4. Rex Hospital, Raleigh, NC (George Adams)
5. St. Luke's Medical Center, Phoenix, AZ (Mansour Assar)
6. Gotham Cardiovascular Research, PC, New York, NY (Cezar Staniloae)
7. Mission Research Institute, New Braunfels, TX (Jason Yoho, Jamison Wyatt)
8. Arkansas Heart Hospital Clinic, Little Rock, AR (Ian Cawich)
9. El Paso Cardiology Associates, El Paso, TX (Mohammad Raja)
10. Mercy Gilbert Medical Center, Chandler, AZ (Georges Nseir)
11. First Coast Cardiovascular Institute, Jacksonville, FL (Issam Moussa, Vaqar Ali)
12. St. John Hospital and Medical Center, Detroit, MI (Thomas Davis)
13. Duke University Hospital, Lumberton, NC (Schuyler Jones)
14. Houston Methodist Sugar Land Hospital, Sugar Land, TX (Imran Mohiuddin)
15. KentuckyOne Health, Lexington, KY (Kiran Saraff)
16. Premier Surgical Associates, Knoxville, TN (George Pliagas)
17. San Antonio Endovascular & Heart Institute, San Antonio, TX (Stefan Kiesz)
18. Midwest Cardiovascular Research Foundation, Davenport, IA (Nicolas Shammas)
19. Riverside Methodist Hospital/Ohio Health, Columbus, OH (John Phillips)
20. Cardiovascular Associates of East Texas, Tyler, TX (Jeffrey Carr)
21. Memorial Hospital of Carbondale, Carbondale, IL (Raed Al-Dallow)
22. Colorado Heart and Vascular, Lakewood, CO (Sameer K Mehta, John Altman)<sup>a</sup>
23. University Surgical Associates, Chattanooga, TN (Mark Fugate, Christopher LeSar)
24. Columbia University Medical Center, New York, NY (William Gray, Philip Green)
25. VA Eastern Colorado Health Care System-Denver VAMC, Denver, CO (Ehrin Armstrong)
26. Michigan Outpatient Vascular Institute, Dearborn, MI (Elias Kassab)
27. Cardiothoracic and Vascular Surgeons/CTVS, Austin, TX (Mazin Foteh)

28. Shady Grove Adventist Hospital, Rockville, MD (Jeffrey Wang)
29. Lester E. Cox Medical Centers, Springfield, MO (Robert Vorhies)
30. Baptist Memorial Hospital DeSoto, Southaven, MS (Stevan Himmelstein, Gilbert Zoghbi)
31. Wellmont CVA Heart Institute, Kingsport, TN (Chris Metzger)
32. Clearwater Cardiovascular & Interventional Consultants, Clearwater, FL (Richard Sola, Saihari Sadanandan)
33. Baptist Cardiac and Vascular Institute, Miami, FL (Ripal Gandhi)
34. Providence Health Center, Waco, TX (M. Wayne Falcone, Adam Falcone)
35. The Heart Institute at Largo, Largo, FL (Jesse Klein)
36. Hartford Hospital, Hartford, CT (Immad Sadiq)
37. Yale-New Haven Hospital, New Haven, CT (Jeffrey Indes, Timur Sarac)
38. Saint Luke's Hospital, Kansas City, MO (Steven Laster)
39. Sanford Research, Sioux Falls, SD (Patrick Kelly)
40. Mount Sinai Medical Center Heart Institute Miami, Miami Beach, FL (Robert Beasley)
41. Radiology and Imaging Specialists of Lakeland, P.A., Lakeland, FL (Lawrence Whitney)
42. University of Texas Medical Branch at Galveston, Galveston, TX (Michael Silva)
43. Florida Hospital Tampa, Pepin Heart Institute, Tampa, FL (Asad Sawar)
44. Florida Hospital, Orlando, FL (Mark Ranson)
45. St. John's Hospital Springfield, Springfield, IL (Jeffrey Goldstein)
46. Metropolitan Heart Institute, Coon Rapids, MN (Daniel Dulas)
47. Houston Methodist Hospital Research Institute, Houston, TX (Alpesh Shah)
48. St. John Health System, Tulsa, OK (Thomachan Kalapura)
49. Chicago Vascular Clinic, Schaumburg, IL (Parag Doshi)
50. Phoenix Heart Cardiovascular Lab, Glendale, AZ (Rajul Patel)
51. Cedars-Sinai Heart Institute, Los Angeles, CA (Guy Mayeda)

<sup>a</sup>Follow-up visits for some subjects enrolled at this site performed at HealthONE Clinic Services - Cardiovascular, LLC, Denver, CO (Sameer K. Mehta).

### **Steering Committee**

George Adams\*, Gary Ansel\*, David Cohen, William Gray\*, William R. Hiatt, Michael R. Jaff, Jihad Mustapha\*, Manesh Patel, Kevin Rogers, Krishna Rocha-Singh

\*National Principal Investigator.

**One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Long-term Clinical Outcomes of Peripheral Endovascular Device Interventions** Jihad Mustapha et al.

**Supplementary Table 1. Subject Accountability.**

	Baseline Rutherford Category (RC)		
	RC2,3	RC4,5	RC6
Number of subjects enrolled	n=501	n=603	n=100
Exited prior to procedure	1	14	0
Site closure <sup>a</sup>	1	14	0
Subjects with procedure data	500	589	100
Exited between procedure and 30-day visit window close	18	21	13
Death	4	2	6
Site closure <sup>a</sup>	1	0	0
Withdrawal/lost to follow-up	13	19	7
Eligible for 30-day follow-up (window $\pm$ 15 days)	482	568	87
Completed	470	533	77
Missed	12	35	10
Exited between 30-day and 6-month visit window close	25	64	16
Death	12	26	7
Site closure <sup>a</sup>	1	6	1
Withdrawal/lost to follow-up	12	32	8
Eligible for 6-month follow-up (window $\pm$ 30 days)	457	504	71
Completed	415	437	55
Missed	42	67	16
Exited between 6-month and 12-month visit window close	42	63	14
Death	8	16	8
Withdrawal/lost to follow-up	34	47	6
Eligible for 12-month follow-up (window $\pm$ 60 days)	415	441	57
Completed	388	402	41
Missed	27	39	16

<sup>a</sup> Site closed without Principal Investigator review.

**One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Long-term Clinical Outcomes of Peripheral Endovascular Device Interventions** Jihad Mustapha et al.

**Supplementary Table 2.** Procedure and Postprocedure Characteristics.<sup>a</sup>

	Baseline Rutherford Category (RC)			p		
	RC2,3 (n=500 <sup>b</sup> )	RC4,5 (n=589 <sup>b</sup> )	RC6 (n=100 <sup>b</sup> )	RC2,3 vs RC4,5	RC2,3 vs RC6	RC4,5 vs RC6
Lesions treated per subject	1.2±0.5 [1.0, IQR 1.0, 1.0]	1.3±0.6 [1.0, IQR 1.0, 2.0]	1.5±0.7 [1.0, IQR 1.0, 2.0]	0.004	<0.001	0.008
1	405/497 (81.5)	429/588 (73.0)	64/99 (64.6)	0.001	<0.001	0.09
2	77/497 (15.5)	136/588 (23.1)	22/99 (22.2)	0.002	0.11	0.90
3 or more	15/497 (3.0)	23/588 (3.9)	13/99 (13.1)	0.51	<0.001	0.001
Procedure time, min	72.2±43.5 (n=499) [65.0, IQR 39.0, 92.0]	82.8±45.5 (n=588) [71.0, IQR 50.0, 103.5]	79.4±44.9 [67.0, IQR 49.0, 97.5]	<0.001	0.14	0.48
Total fluoroscopy time, min	(n=497 23.9±18.7 {19.0, IQR 12.0, 30.7}	(n=585 26.9±17.6 [22.5, IQR 15.3, 32.4]	(n=99) 25.5±21.1 [18.3, IQR 12.7, 28.6]	0.007	0.44	0.49
Contrast volume, mL	167.7±88.5 (n=499) [150.0, IQR 100.0, 213.0]	169.4±91.6 (n=586) [155.0, IQR 102.0, 215.0]	146.3±95.0 [125.0, IQR 75.0, 200.0]	0.76	0.03	0.02
Change in target limb runoff patency <sup>c</sup>						
Worsened	10/303 (3.3)	8/423 (1.9)	1/65 (1.5)	0.24	0.70	>0.99
No change	245/303 (80.9)	279/423 (66.0)	39/65 (60.0)	<0.001	<0.001	0.40
Improved	48/303 (15.8)	136/423 (32.2)	25/65 (38.5)	<0.001	<0.001	0.32

Discharge disposition						
Home	498 (99.6)	563 (95.6)	78 (78.0)	<0.001	<0.001	<0.001
Another acute care hospital	2 (0.4)	3 (0.5)	0 (0.0)	>0.99	>0.99	>0.99
Rehab hospital	0 (0.0)	4 (0.7)	11 (11.0)	0.13	<0.001	<0.001
Skilled nursing facility	0 (0.0)	19 (3.2)	7 (7.0)	<0.001	<0.001	0.08
Hospice	0 (0.0)	0 (0.0)	1 (1.0)	—	0.17	0.15
Died prior to discharge	0 (0.0)	0 (0.0)	3 (3.0)	—	0.005	0.003

<sup>a</sup> Continuous data are presented as the mean  $\pm$  standard deviation [median, interquartile range (IQR) Q1, Q3]; categorical data are given as the number (percentage). P values determined from Monte Carlo approximation of a Fisher exact test (categorical) or ANOVA (continuous).

<sup>b</sup> Number of lesions unless otherwise noted.

<sup>c</sup> By core laboratory; patency defined as any flow without total occlusion.

**One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Long-term Clinical Outcomes of Peripheral Endovascular Device Interventions** Jihad Mustapha et al.

**Supplementary Table 3.** Freedom from Major Adverse Events through 12 Months.<sup>a</sup>

Freedom from	Baseline Rutherford Category (RC)			p		
	RC2,3 (n=500)	RC4,5 (n=589)	RC6 (n=100)	RC2,3 vs RC4,5	RC2,3 vs RC6	RC4,5 vs RC6
MAE at 30 days	99.2 (98.4 to 100)	96.1 (94.5 to 97.6)	90.8 (85.1 to 96.5)	0.001	<0.001	0.02
Major amputation	100.0	98.8 (97.9 to 99.7)	95.8 (91.9 to 99.8)	0.02	<0.001	0.03
TVR	99.6 (99.0 to 100.2)	97.3 (95.9 to 98.6)	97.9 (95.0 to 100.8)	0.003	0.07	0.72
Death	99.6 (99.0 to 100.2)	99.7 (99.2 to 100.1)	95.9 (92.0 to 99.8)	0.86	0.001	<0.001
MAE at 6 months	93.0 (90.7 to 95.3)	82.4 (79.2 to 85.6)	74.5 (65.4 to 83.6)	<0.001	<0.001	0.04
Major amputation	99.8 (99.4 to 100.2)	96.8 (95.3 to 98.3)	87.5 (80.6 to 94.5)	<0.001	<0.001	<0.001
TVR	93.4 (91.2 to 95.7)	84.3 (81.2 to 87.4)	85.7 (78.1 to 93.2)	<0.001	0.01	0.77
Death <sup>b</sup>	97.1 (95.6 to 98.6)	95.2 (93.4 to 96.9)	85.8 (78.6 to 93.0)	0.11	<0.001	<0.001
12-Month MAE	82.6 (79.1 to 86.1)	73.2 (69.3 to 77.0)	59.3 (48.4 to 70.1)	<0.001	<0.001	0.005
Major amputation	99.3 (98.6 to 100.1)	96.0 (94.4 to 97.6)	81.7 (73.2 to 90.2)	0.001	<0.001	<0.001
TVR	83.2 (79.7 to 86.6)	75.4 (77.7 to 79.1)	72.6 (62.4 to 82.7)	0.001	0.01	0.71
Death <sup>b</sup>	95.8 (94.0 to 97.6)	92.2 (89.9 to 94.5)	76.2 (67.2 to 85.1)	0.02	<0.001	<0.001

Abbreviations: MAE, major adverse event; TVR, target vessel revascularization

<sup>a</sup> Values presented as estimated survival rate (95% confidence interval).

<sup>b</sup> Includes all-death, including those beyond 30 days.

**One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Long-term Clinical Outcomes of Peripheral Endovascular Device Interventions** Jihad Mustapha et al.

**Supplementary Table 4.** Change in EuroQoL Five Dimensions Questionnaire Through 12 Months.<sup>a</sup>

	Baseline	30 Days		6 Months		12 Months	
	Score	Score	Change from Baseline	Score	Change from Baseline	Score	Change from Baseline
RC2,3							
VAS	(n=496) 68.3±19.7 [70.0, IQR 50.0, 81.5]	(n=460) 75.0±17.9 [80.0, IQR 65.0, 90.0]	(n=457) 6.3±20.8 p<0.001	(n=405) 73.8±17.9 [78.0, IQR 65.0, 90.0]	(n=402) 5.0±20.6 p<0.001	(n=386) 74.3±17.6 [78.5, IQR 65.0, 90.0]	(n=383) 5.4±21.2 p<0.001
Mobility	(n=495) 2.7±1.0 [3.0, IQR 2.0, 3.0]	(n=460) 2.1±1.0 [2.0, IQR 1.0, 3.0]	(n=456) -0.6±1.1 p<0.001	(n=405) 2.2±1.1 [2.0, IQR 1.0, 3.0]	(n=401) -0.4±1.1 p<0.001	(n=386) 2.2±1.0 [2.0, IQR 1.0, 3.0]	(n=382) -0.5±1.1 p<0.001
Self-care	(n=496) 1.3±0.7 [1.0, IQR 1.0, 1.0]	(n=460) 1.2±0.6 [1.0, IQR 1.0, 1.0]	(n=456) -0.6±1.1 p=0.01	(n=405) 1.3±0.6 [1.0, IQR 1.0, 1.0]	(n=401) -0.4±1.1 p=0.30	(n=386) 1.3±0.7 [1.0, IQR 1.0, 1.0]	(n=382) -0.5±1.1 p=0.84
Usual activities	(n=496) 2.2±1.1 [2.0, IQR 1.0, 3.0]	(n=460) 1.8±1.0 [2.0, IQR 1.0, 2.5]	(n=457) -0.4±1.1 p<0.001	(n=405) 1.9±1.0 [2.0, IQR 1.0, 3.0]	(n=402) -0.3±1.2 p<0.001	(n=386) 1.9±1.0 [2.0, IQR 1.0, 3.0]	(n=383) -0.3±1.1 p<0.001
Pain/ discomfort	(n=496) 2.7±1.1 [3.0, IQR 2.0, 3.0]	(n=460) 2.1±1.0 [2.0, IQR 1.0, 3.0]	(n=457) -0.6±1.3 p<0.001	(n=405) 2.1±1.0 [2.0, IQR 1.0, 3.0]	(n=402) -0.5±1.3 p<0.001	(n=385) 2.2±1.0 [2.0, IQR 1.0, 3.0]	(n=382) -0.4±1.2 p<0.001
Anxiety/ depression	(n=496) 1.7±0.9 [1.0, IQR	(n=460) 1.5±0.8 [1.0, IQR	(n=457) -0.2±1.0 p<0.001	(n=405) 1.5±0.8 [1.0, IQR	(n=402) -0.2±0.9 p<0.001	(n=385) 1.5±0.8 [1.0, IQR	(n=382) -0.1±0.9 p=0.002

	1.0, 2.0]	1.0, 2.0]		1.0, 2.0]		1.0, 2.0]	
RC4,5							
VAS	(n=584) 64.1±20.0 [65.0, IQR 50.0, 80.0]	(n=526) 69.1±19.0 [75.0, IQR 50.0, 80.0]	(n=522) 4.6±19.9 p<0.001	(n=435) 69.6±19.3 [75.0, IQR 55.0, 85.0]	(n=432) 4.5±21.9 p<0.001	(n=400) 70.8±19.5 [75.0, IQR 60.0, 85.0]	(n=397) 5.9±22.3 p<0.001
Mobility	(n=584) 3.0±1.1 [3.0, IQR 2.0, 4.0]	(n=526) 2.6±1.1 [3.0, IQR 2.0, 3.0]	(n=522) -0.4±1.2 p<0.001	(n=435) 2.5±1.1 [3.0, IQR 2.0, 3.0]	(n=432) -0.4±1.2 p<0.001	(n=400) 2.5±1.1 [3.0, IQR 1.0, 3.0]	(n=397) -0.4±1.3 p<0.001
Self-care	(n=584) 1.7±1.0 [1.0, IQR 1.0, 2.0]	(n=527) 1.6±1.0 [1.0, IQR 1.0, 2.0]	(n=522) -0.4±1.2 p=0.13	(n=435) 1.5±1.0 [1.0, IQR 1.0, 2.0]	(n=432) -0.4±1.2 p=0.08	(n=400) 1.5±1.0 [1.0, IQR 1.0, 2.0]	(n=397) -0.4±1.3 p=0.07
Usual activities	(n=583) 2.6±1.2 [3.0, IQR 2.0, 3.0]	(n=526) 2.4±1.2 [2.0, IQR 1.0, 3.0]	(n=521) -0.2±1.2 p<0.001	(n=435) 2.2±1.2 [2.0, IQR 1.0, 3.0]	(n=431) -0.4±1.3 p<0.001	(n=400) 2.2±1.2 [2.0, IQR 1.0, 3.0]	(n=396) -0.3±1.3 p<0.001
Pain/ discomfort	(n=584) 2.9±1.1 [3.0, IQR 2.0, 4.0]	(n=527) 2.4±1.1 [2.0, IQR 2.0, 3.0]	(n=523) -0.5±1.3 p<0.001	(n=435) 2.4±1.1 [2.0, IQR 1.0, 3.0]	(n=432) -0.5±1.4 p<0.001	(n=400) 2.3±1.1 [2.0, IQR 1.0, 3.0]	(n=397) -0.6±1.2 p<0.001
Anxiety/ depression	(n=584) 1.9±1.0 [2.0, IQR 1.0, 3.0]	(n=526) 1.7±1.0 [1.0, IQR 1.0, 2.0]	(n=522) -0.2±1.1 p<0.001	(n=435) 1.6±0.9 [1.0, IQR 1.0, 2.0]	(n=432) -0.3±1.1 p<0.001	(n=400) 1.6±0.9 [1.0, IQR 1.0, 2.0]	(n=397) -0.3±1.0 p<0.001
RC6							
VAS	(n=96) 56.9±20.2 [60.0, IQR 50.0, 70.0]	(n=76) 64.4±21.1 [70.0, IQR 50.0, 80.0]	(n=73) 4.9±19.3 p=0.03	(n=52) 65.4±21.9 [72.5, IQR 50.0, 80.0]	(n=52) 5.7±24.0 p=0.09	(n=39) 70.9±19.9 [75.0, IQR 60.0, 85.0]	(n=38) 13.8±20.6 p<0.001
Mobility	(n=96) 3.5±1.1	(n=76) 3.0±1.3	(n=73) -0.5±1.3	(n=52) 3.2±1.4	(n=52) -0.4±1.4	(n=39) 2.9±1.5	(n=38) -0.8±1.5



	[4.0, IQR 3.0, 4.0]	[3.0, IQR 2.0, 4.0]	p=0.004	[3.0, IQR 2.0, 4.5]	p=0.04	[3.0, IQR 2.0, 4.0]	p=0.004
Self-care	(n=96) 2.5±1.4 [2.0, IQR 1.0, 3.0]	(n=76) 2.1±1.1 [2.0, IQR 1.0, 3.0]	(n=73) -0.5±1.3 p=0.07	(n=52) 1.9±1.1 [2.0, IQR 1.0, 3.0]	(n=52) -0.4±1.4 p<0.001	(n=39) 1.6±0.9 [1.0, IQR 1.0, 2.0]	(n=38) -0.8±1.5 p=0.003
Usual activities	(n=96) 3.2±1.2 [3.0, IQR 3.0, 4.0]	(n=76) 2.9±1.3 [3.0, IQR 2.0, 4.0]	(n=73) -0.3±1.2 p=0.05	(n=52) 2.8±1.2 [3.0, IQR 2.0, 3.5]	(n=52) -0.5±1.5 p=0.02	(n=39) 2.3±1.2 [2.0, IQR 1.0, 3.0]	(n=38) -0.9±1.3 p<0.001
Pain/ discomfort	(n=96) 3.1±1.2 [3.0, IQR 2.0, 4.0]	(n=76) 2.7±1.2 [3.0, IQR 2.0, 3.0]	(n=73) -0.4±1.3 p=0.03	(n=52) 2.4±1.1 [2.0, IQR 2.0, 3.0]	(n=52) -0.5±1.2 p=0.003	(n=39) 2.2±1.0 [2.0, IQR 1.0, 3.0]	(n=38) -0.6±1.1 p=0.002
Anxiety/ depression	(n=96) 2.1±1.1 [2.0, IQR 1.0, 3.0]	(n=76) 1.9±1.1 [1.5, IQR 1.0, 2.5]	(n=73) -0.2±1.1 p=0.19	(n=52) 1.8±0.9 [1.5, IQR 1.0, 2.5]	(n=52) -0.4±1.2 p=0.02	(n=39) 1.6±0.8 [1.0, IQR 1.0, 2.0]	(n=38) -0.5±1.0 p=0.003

Abbreviation: RC, Rutherford category; VAS, visual analog scale.

<sup>a</sup> Values are presented as the mean ± standard deviation [median, interquartile range (IQR)]. EuroQoL Five Dimensions Questionnaire is a standardized instrument as a measure of health outcome. Higher VAS scores indicate higher patient self-scoring of health; lower dimension scores indicate a better rating of health.

**One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Long-term Clinical Outcomes of Peripheral Endovascular Device Interventions** Jihad Mustapha et al.

**Supplementary Table 5.** Change in the Vascular Quality of Life Questionnaire through 12 Months.<sup>a</sup>

	Baseline	30 Days		6 Months		12 Months	
	Score	Score	Change from Baseline	Score	Change from Baseline	Score	Change from Baseline
RC2,3							
Total	(n=491) 4.2±1.3 [4.2, IQR 3.3, 5.3]	(n=456) 5.4±1.3 [5.7, IQR 4.6, 6.5]	(n=450) 1.1±1.2 p<0.001	(n=401) 5.4±1.2 [5.6, IQR 4.5, 6.5]	(n=396) 1.1±1.2 p<0.001	(n=381) 5.3±1.3 [5.7, IQR 4.4, 6.4]	(n=376) 1.0±1.3 p<0.001
Physical activity	(n=494) 3.7±1.4 [3.6, IQR 2.6, 4.8]	(n=458) 5.0±1.5 [5.3, IQR 3.9, 6.3]	(n=455) 1.3±1.5 p<0.001	(n=401) 4.9±1.4 [5.1, IQR 4.0, 6.3]	(n=398) 1.2±1.4 p<0.001	(n=383) 4.9±1.5 [5.1, IQR 3.8, 6.1]	(n=380) 1.1±1.5 p<0.001
Symptom	(n=495) 4.8±1.3 [5.0, IQR 4.0, 5.8]	(n=458) 5.7±1.1 [6.0, IQR 5.0, 6.5]	(n=454) 0.8±1.2 p<0.001	(n=405) 5.7±1.1 [6.0, IQR 5.0, 6.5]	(n=401) 0.8±1.2 p<0.001	(n=385) 5.6±1.2 [5.8, IQR 5.0, 6.5]	(n=381) 0.7±1.2 p<0.001
Pain	(n=496) 3.8±1.6 [3.8, IQR 2.6, 5.0]	(n=460) 5.1±1.6 [5.3, IQR 4.0, 6.4]	(n=457) 1.2±1.5 p<0.001	(n=405) 5.1±1.6 [5.5, IQR 4.0, 6.5]	(n=403) 1.2±1.5 p<0.001	(n=384) 4.9±1.6 [5.3, IQR 3.8, 6.5]	(n=382) 1.1±1.6 p<0.001
Emotional	(n=495) 4.6±1.6 [4.7, IQR 3.4, 6.0]	(n=460) 5.7±1.4 [6.1, IQR 4.9, 6.9]	(n=456) 1.0±1.4 p<0.001	(n=405) 5.8±1.3 [6.3, IQR 5.0, 6.9]	(n=402) 1.0±1.4 p<0.001	(n=382) 5.7±1.4 [6.3, IQR 4.9, 6.9]	(n=379) 1.0±1.5 p<0.001
Social	(n=497) 4.8±1.9	(n=460) 5.7±1.6	(n=458) 0.9±1.7	(n=404) 5.9±1.5	(n=402) 1.0±1.7	(n=385) 5.8±1.5	(n=383) 1.0±1.8

	[5.0, IQR 3.5, 7.0]	[6.5, IQR 4.5, 7.0]	p<0.001	[6.5, IQR 5.0, 7.0]	p<0.001	[6.5, IQR 5.0, 7.0]	p<0.001
RC4,5							
Total	(n=582) 3.7±1.4 [3.6, IQR 2.6, 4.8]	(n=519) 4.8±1.4 [5.0, IQR 3.8, 6.0]	(n=516) 1.0±1.3 p<0.001	(n=432) 4.9±1.4 [5.0, IQR 3.9, 6.2]	(n=428) 1.1±1.4 p<0.001	(n=395) 5.0±1.4 [5.2, IQR 4.0, 6.3]	(n=391) 1.2±1.4 p<0.001
Physical activity	(n=589) 3.2±1.4 [3.0, IQR 2.1, 4.1]	(n=522) 4.3±1.6 [4.3, IQR 3.0, 5.6]	(n=519) 1.0±1.5 p<0.001	(n=433) 4.4±1.6 [4.4, IQR 3.3, 5.8]	(n=431) 1.1±1.6 p<0.001	(n=396) 4.5±1.6 [4.5, IQR 3.3, 5.9]	(n=394) 1.1±1.6 p<0.001
Symptom	(n=584) 4.2±1.5 [4.3, IQR 3.3, 5.4]	(n=526) 5.2±1.3 [5.5, IQR 4.5, 6.3]	(n=523) 1.0±1.3 p<0.001	(n=435) 5.3±1.3 [5.5, IQR 4.3, 6.5]	(n=432) 1.0±1.4 p<0.001	(n=398) 5.4±1.3 [5.5, IQR 4.5, 6.5]	(n=395) 1.1±1.4 p<0.001
Pain	(n=585) 3.4±1.7 [3.3, IQR 2.0, 4.5]	(n=526) 4.6±1.7 [4.8, IQR 3.3, 6.0]	(n=523) 1.2±1.7 p<0.001	(n=435) 4.7±1.7 [4.8, IQR 3.5, 6.3]	(n=433) 1.3±1.9 p<0.001	(n=396) 4.8±1.7 [5.4, IQR 3.5, 6.3]	(n=394) 1.4±1.9 p<0.001
Emotional	(n=585) 4.1±1.7 [4.0, IQR 2.7, 5.4]	(n=526) 5.1±1.6 [5.4, IQR 4.0, 6.6]	(n=523) 1.0±1.5 p<0.001	(n=435) 5.3±1.6 [5.7, IQR 4.1, 6.7]	(n=433) 1.1±1.6 p<0.001	(n=398) 5.4±1.6 [5.9, IQR 4.4, 6.7]	(n=396) 1.3±1.6 p<0.001
Social	(n=583) 4.3±1.9 [4.0, IQR 2.5, 6.0]	(n=525) 5.2±1.8 [5.5, IQR 3.5, 7.0]	(n=522) 0.9±1.9 p<0.001	(n=434) 5.4±1.7 [6.0, IQR 4.0, 7.0]	(n=431) 1.1±2.0 p<0.001	(n=396) 5.5±1.7 [6.0, IQR 4.0, 7.0]	(n=396) 1.2±2.0 p<0.001
RC6							
Total	(n=93) 3.1±1.2 [3.0, IQR 2.3, 3.8]	(n=72) 4.1±1.5 [4.1, IQR 3.0, 5.4]	(n=69) 1.0±1.5 p<0.001	(n=50) 4.4±1.4 [4.8, IQR 3.1, 5.5]	(n=49) 1.2±1.4 p<0.001	(n=39) 4.8±1.3 [4.9, IQR 3.6, 6.0]	(n=37) 1.5±1.2 p<0.001
Physical	(n=94)	(n=74)	(n=70)	(n=50)	(n=49)	(n=39)	(n=38)

activity	2.4±1.1 [2.1, IQR 1.6, 3.1]	3.5±1.6 [3.4, IQR 2.1, 4.6]	1.1±1.5 p<0.001	3.5±1.5 [3.4, IQR 2.4, 4.4]	0.9±1.5 p<0.001	4.0±1.7 [4.0, IQR 2.6, 5.5]	1.3±1.3 p<0.001
Symptom	(n=95) 3.8±1.6 [3.8, IQR 2.5, 5.0]	(n=75) 4.6±1.6 [5.0, IQR 3.3, 6.0]	(n=72) 0.8±1.9 <0.001	(n=51) 4.9±1.5 [5.3, IQR 4.5, 6.3]	(n=51) 1.1±1.8 <0.001	(n=39) 5.3±1.3 [5.3, IQR 4.5, 6.5]	(n=38) 1.6±1.5 p<0.001
Pain	(n=94) 3.3±1.9 [2.5, IQR 1.5, 4.5]	(n=74) 4.2±1.8 [4.3, IQR 2.8, 5.8]	(n=71) 0.8±1.8 p<0.001	(n=51) 4.5±1.8 [4.5, IQR 3.3, 6.3]	(n=50) 1.1±2.1 p<0.001	(n=39) 4.8±1.6 [5.0, IQR 3.8, 6.0]	(n=37) 1.4±2.0 p<0.001
Emotional	(n=94) 3.4±1.5 [3.3, IQR 2.1, 4.3]	(n=75) 4.5±1.7 [4.7, IQR 3.3, 6.0]	(n=71) 1.1±1.8 p<0.001	(n=51) 5.1±1.7 [5.6, IQR 3.7, 6.4]	(n=50) 1.5±1.7 p<0.001	(n=39) 5.2±1.4 [5.4, IQR 4.6, 6.4]	(n=38) 1.7±1.6 p<0.001
Social	(n=94) 3.5±1.7 [3.5, IQR 2.0, 4.5]	(n=74) 4.4±2.0 [4.5, IQR 2.5, 6.0]	(n=70) 0.8±2.0 p<0.001	(n=51) 4.9±1.8 [5.0, IQR 3.5, 6.5]	(n=50) 1.3±1.7 p<0.001	(n=39) 5.2±1.6 [5.5, IQR 4.0, 6.5]	(n=38) 1.5±2.0 p<0.001

Abbreviation: RC, Rutherford category.

<sup>a</sup> Values are presented as the mean ± standard deviation [median, interquartile range (IQR) Q1, Q3]. The Vascular Quality of Life Questionnaire is a health-related quality of life instrument specially related to peripheral artery disease; higher subdomain scores indicate better rating of health.